Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report

Chimeric antigen receptor (CAR)-modified T-cells targeting CD19 represent a promising therapy for relapsed or refractory (r/r) lymphoma and leukemia. The most common adverse events are immune related and include cytokine release syndrome and neurotoxicity. However, early and late hematological toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Baur, Rebecca, Jitschin, Regina, Kharboutli, Soraya, Stoll, Andrej, Völkl, Simon, Büttner-Herold, Maike, Schmidt, Daniela, Rösler, Wolf, Mackensen, Andreas, Mougiakakos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287610/
https://www.ncbi.nlm.nih.gov/pubmed/34272307
http://dx.doi.org/10.1136/jitc-2021-002721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287610/
https://www.ncbi.nlm.nih.gov/pubmed/34272307
http://dx.doi.org/10.1136/jitc-2021-002721

Ejemplares similares